v3.26.1
Net Loss per Share - Schedule of computation of basic and diluted net loss per share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Numerator          
Net loss $ (46,436) $ (36,965) $ (89,057) $ (74,917)  
Less: Net loss attributable to noncontrolling interest $ (18,014) $ (20,413) $ (40,598) $ (41,631)  
Antidilutive securities          
Earnout Rights     17,500,000 17,500,000  
Stock options granted under the 2022 Equity Incentive Plan 39,826,692 30,504,248 39,826,692 30,504,248  
Restricted Stock Rights [Member]          
Antidilutive securities          
Unvested Restricted Stock Rights     0 742,684  
Common Class A [Member]          
Numerator          
Net loss Available To Class A ordinary Shareholders of ProKidney Corp., Basic $ (28,422) $ (16,552) $ (48,459) $ (33,286)  
Net loss Available To Class A ordinary Shareholders of ProKidney Corp., Diluted $ (28,422) $ (16,552) $ (48,459) $ (33,286)  
Denominator          
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Basic 186,560,999 130,730,840 164,366,352 129,858,450  
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Diluted 186,560,999 130,730,840 164,366,352 129,858,450  
Net loss per share attributable to Class A common stock, Basic $ (0.15) $ (0.13) $ (0.29) $ (0.26)  
Net loss per share attributable to Class A common stock, Diluted $ (0.15) $ (0.13) $ (0.29) $ (0.26)  
Antidilutive securities          
ProKidney Corp. ordinary shares 205,716,189   205,716,189   141,807,277
Common Class B [Member]          
Antidilutive securities          
ProKidney Corp. ordinary shares 96,596,315 159,288,931 96,596,315 159,288,931 159,262,779